Growth Hormone Therapy in Liver Cirrhosis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

January 15, 2018

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Cirrhosis, Liver
Interventions
DRUG

Standard Medical Therapy

Standard Medical Therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics as required

DRUG

Growth Hormone

GH therapy is initiated at a low dose of 1U/day and titrated slowly upward to a maximum dose of 3U/day (depending on IGF-1 levels) subcutaneously for 1 year.

Trial Locations (1)

160012

Post Graduate Institute of Medical Education and Research, Chandigarh

All Listed Sponsors
lead

Post Graduate Institute of Medical Education and Research, Chandigarh

OTHER

NCT03420144 - Growth Hormone Therapy in Liver Cirrhosis | Biotech Hunter | Biotech Hunter